Start reading
Curated research summaries and study-literacy guides, each tied to primary sources.
ResearchBPC-157 research: animal models, sparse human reports, and what is still unknownAn evidence map for stable gastric pentadecapeptide BPC-157 — preclinical cytoprotection literature, limited human case reports, and regulatory context. Educational only.Read article →
ResearchCT-G32 (SCO-940): four-receptor preclinical data and sponsor disclosuresEditorial map of Scohia/Celltrion CT-G32 (SCO-940) TIDES Europe 2026 disclosures: four-receptor concept, rat preclinical comparisons, evidence limits vs human retatrutide trials.Read article →
ResearchRetatrutide phase 2 obesity trial: published human data and regulatory contextSummary of the NEJM phase 2 retatrutide trial (LY3437943, NCT04881760): eligibility, endpoints, weight outcomes, separate diabetes trial, and FDA-sourced status notes.Read article →
ResearchTB-500 and thymosin beta-4: why research names are not interchangeableTB-500 is a research peptide label tied to a thymosin β4 fragment; FDA-reviewed thymosin beta-4 drug programs are a separate evidence line. Educational comparison with primary sources.Read article →
ResearchUBT251 phase 2 in China: Cell Metabolism trial map (not a retatrutide comparison)Editorial summary of the UBT251 triple-agonist phase 2 paper (DOI 10.1016/j.cmet.2026.09.021, NCT07177469): design, LS mean weight change at 24 weeks, limits, and why social cross-trial numbers mislead.Read article →
Study literacy
Seven research questions to ask before you trust a peptide study claim
A checklist for judging peptide papers and trial posts: species, registration, endpoints, compound identity, conflicts, and what counts as human evidence.
Open checklist →FAQ
Research vs treatment, before/after claims, wearables, and how CT632 pairs with PeptIQ.
PeptIQ blog
Longer guides and policy context on Kris’s education hub (separate site).